Talthera, Inc. Faces Delisting Concerns

TL;DR

Talthera's in trouble, might get delisted.

AI Summary

Talthera, Inc. (formerly AcelRx Pharmaceuticals Inc.) filed an 8-K on December 11, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates a change in listing status, with the earliest event reported on December 6, 2024.

Why It Matters

This filing signals potential issues with Talthera's continued listing on an exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — Delisting notices indicate significant financial or operational distress, posing a substantial risk to investors.

Key Players & Entities

• Talthera, Inc. (company) — Registrant
• AcelRx Pharmaceuticals Inc. (company) — Former company name
• December 6, 2024 (date) — Earliest event reported
• December 11, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Global Mar
• $1.00 — ties to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(

Filing Documents

• acrx20241210_8k.htm (8-K) — 24KB
• 0001437749-24-037242.txt ( ) — 157KB
• tlph-20241206.xsd (EX-101.SCH) — 3KB
• tlph-20241206_def.xml (EX-101.DEF) — 12KB
• tlph-20241206_lab.xml (EX-101.LAB) — 15KB
• tlph-20241206_pre.xml (EX-101.PRE) — 12KB
• acrx20241210_8k_htm.xml (XML) — 3KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 6, 2024, Talphera, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice does not impact the listing of the Company's common stock on The Nasdaq Global Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of ten consecutive business days before June 4, 2025. In the event that the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period by effecting a reverse stock split if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice to the Company that its common stock will be subject to delisting. The Company inte

Forward-Looking Statements

Forward-Looking Statements Certain of the statements made in this report are forward-looking, such as those, among others, relating to the Company's ability to regain compliance with the Minimum Bid Price and the Company's intentions to actively monitor the closing bid price of its common stock and to evaluate available options to regain compliance with the minimum bid price requirement within the required time period. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 13, 2024. You are cautioned not to place undue reliance on forward-looking statements which are current only as of the date hereof. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 11, 2024 TALPHERA, INC. By: /s/ Raffi Asadorian Raffi Asadorian Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR